{"id":18800,"date":"2018-07-03T13:56:44","date_gmt":"2018-07-03T12:56:44","guid":{"rendered":"https:\/\/www.inovallee.com\/?p=18800"},"modified":"2018-07-03T13:56:44","modified_gmt":"2018-07-03T12:56:44","slug":"nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales","status":"publish","type":"post","link":"https:\/\/www.inovallee.com\/en\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/","title":{"rendered":"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" class=\"alignleft size-medium wp-image-12096\" src=\"https:\/\/www.inovallee.com\/wp-content\/uploads\/NHTheraguix-1-600x400.png\" alt=\"\" width=\"600\" height=\"400\" \/>Implant\u00e9e au Tarmac depuis mars 2017, <a href=\"http:\/\/nhtheraguix.com\/\">NH TherAguix<\/a> est une startup en biotechnologie qui d\u00e9veloppe une plateforme technologique de nanoparticules radiosensibilisantes \u00e0 administration intraveineuse, fruit de dix ann\u00e9es de recherche acad\u00e9mique internationale. AGuIX\u00ae son m\u00e9dicament candidat est actuellement en phase d\u2019\u00e9valuation clinique.<br \/>\nNHTherAguix vient d\u2019annoncer la soumission \u00e0 l&rsquo;ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.\u00a0 Il s\u2019inscrit dans la continuit\u00e9 de l&rsquo;essai de Phase 1b NANORAD1 qui a d\u00e9but\u00e9 en Juillet 2017 (First In Man) et\u00a0dont l&rsquo;inclusion s&rsquo;est achev\u00e9e avec succ\u00e8s en F\u00e9vrier 2018 (15 patients). Les m\u00e9tastases c\u00e9r\u00e9brales repr\u00e9sentent la 3<sup>i\u00e8me<\/sup> maladie neurologique en terme d\u2019incidence avec plus de 30 000 nouveaux patients par an en France. 30 % des patients souffrant d&rsquo;un cancer syst\u00e9mique sont susceptibles d&rsquo;en d\u00e9velopper. La m\u00e9diane de survie globale reste inf\u00e9rieure \u00e0 6 mois pour ces patients.<br \/>\nEn parall\u00e8le, une premi\u00e8re patiente vient d&rsquo;\u00eatre trait\u00e9e dans le cadre de l\u2019essai clinique de Phase 1b NANOCOL, lequel concerne des patientes atteintes de cancer avanc\u00e9 du col de l&rsquo;ut\u00e9rus. Le cancer du col ut\u00e9rin repr\u00e9sente la 4\u00e8me cause de cancer de la femme dans le monde. En d\u00e9pit des am\u00e9liorations du pronostic gr\u00e2ce aux techniques modernes de curieth\u00e9rapie bas\u00e9es sur l\u2019IRM, le risque de r\u00e9cidive demeure \u00e9lev\u00e9 pour les tumeurs localement \u00e9volu\u00e9es, et gr\u00e8ve consid\u00e9rablement le pronostic des patientes. Cet essai clinique multicentrique est men\u00e9 par l\u2019Institut Gustave Roussy \u00e0 Paris, leader europ\u00e9en du traitement du cancer. L\u2019objectif principal de NANOCOL, est de d\u00e9montrer, sur un cancer primaire et par escalade de dose, la bonne tol\u00e9rance d\u2019AGuIX\u00ae apr\u00e8s injection intraveineuse, dans le cadre d\u2019un protocole de soins standard associant d\u00e9j\u00e0 radioth\u00e9rapie, chimioth\u00e9rapie et curieth\u00e9rapie.<\/p>","protected":false},"excerpt":{"rendered":"<p>Implant\u00e9e au Tarmac depuis mars 2017, NH TherAguix est une startup en biotechnologie qui d\u00e9veloppe une plateforme technologique de nanoparticules radiosensibilisantes \u00e0 administration intraveineuse, fruit de dix ann\u00e9es de recherche acad\u00e9mique internationale. AGuIX\u00ae son m\u00e9dicament candidat est actuellement en phase d\u2019\u00e9valuation clinique. NHTherAguix vient d\u2019annoncer la soumission \u00e0 l&rsquo;ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":12096,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,44],"tags":[],"class_list":["post-18800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-startup-tarmac","category-tarmac-incubator"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e<\/title>\n<meta name=\"description\" content=\"NHTherAguix vient d\u2019annoncer la soumission \u00e0 l&#039;ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.inovallee.com\/en\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e\" \/>\n<meta property=\"og:description\" content=\"NHTherAguix vient d\u2019annoncer la soumission \u00e0 l&#039;ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.inovallee.com\/en\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/\" \/>\n<meta property=\"og:site_name\" content=\"inovall\u00e9e\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/technopoleinovallee\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-03T12:56:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.inovallee.com\/wp-content\/uploads\/2017\/05\/NHTheraguix-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Inovallee\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@inovallee\" \/>\n<meta name=\"twitter:site\" content=\"@inovallee\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Inovallee\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/\"},\"author\":{\"name\":\"Inovallee\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/person\\\/a45b15518aad3111b2d61d257a3e023b\"},\"headline\":\"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales\",\"datePublished\":\"2018-07-03T12:56:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/\"},\"wordCount\":364,\"publisher\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/NHTheraguix-1.png\",\"articleSection\":[\"L'\u00e9cho des startups du Tarmac\",\"Tarmac incubator\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/\",\"name\":\"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/NHTheraguix-1.png\",\"datePublished\":\"2018-07-03T12:56:44+00:00\",\"description\":\"NHTherAguix vient d\u2019annoncer la soumission \u00e0 l'ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/NHTheraguix-1.png\",\"contentUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/NHTheraguix-1.png\",\"width\":900,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.inovallee.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#website\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/\",\"name\":\"inovall\u00e9e technopole, Home to software & smart technologies\",\"description\":\"Home to software &amp; smart technologies\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.inovallee.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\",\"name\":\"inovall\u00e9e\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/inovallee_2022_GrenobleAlpes.png\",\"contentUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/inovallee_2022_GrenobleAlpes.png\",\"width\":945,\"height\":369,\"caption\":\"inovall\u00e9e\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/technopoleinovallee\\\/\",\"https:\\\/\\\/x.com\\\/inovallee\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/inovall-e\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/inovallee?reload=9\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/person\\\/a45b15518aad3111b2d61d257a3e023b\",\"name\":\"Inovallee\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e","description":"NHTherAguix vient d\u2019annoncer la soumission \u00e0 l'ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.inovallee.com\/en\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/","og_locale":"en_GB","og_type":"article","og_title":"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e","og_description":"NHTherAguix vient d\u2019annoncer la soumission \u00e0 l'ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.","og_url":"https:\/\/www.inovallee.com\/en\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/","og_site_name":"inovall\u00e9e","article_publisher":"https:\/\/www.facebook.com\/technopoleinovallee\/","article_published_time":"2018-07-03T12:56:44+00:00","og_image":[{"width":900,"height":600,"url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2017\/05\/NHTheraguix-1.png","type":"image\/png"}],"author":"Inovallee","twitter_card":"summary_large_image","twitter_creator":"@inovallee","twitter_site":"@inovallee","twitter_misc":{"Written by":"Inovallee","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#article","isPartOf":{"@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/"},"author":{"name":"Inovallee","@id":"https:\/\/www.inovallee.com\/#\/schema\/person\/a45b15518aad3111b2d61d257a3e023b"},"headline":"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales","datePublished":"2018-07-03T12:56:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/"},"wordCount":364,"publisher":{"@id":"https:\/\/www.inovallee.com\/#organization"},"image":{"@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#primaryimage"},"thumbnailUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2017\/05\/NHTheraguix-1.png","articleSection":["L'\u00e9cho des startups du Tarmac","Tarmac incubator"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/","url":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/","name":"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales - inovall\u00e9e","isPartOf":{"@id":"https:\/\/www.inovallee.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#primaryimage"},"image":{"@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#primaryimage"},"thumbnailUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2017\/05\/NHTheraguix-1.png","datePublished":"2018-07-03T12:56:44+00:00","description":"NHTherAguix vient d\u2019annoncer la soumission \u00e0 l'ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) du protocole clinique de Phase 2 NANORAD2 portant sur les m\u00e9tastases c\u00e9r\u00e9brales. Cet essai multicentrique fran\u00e7ais sera pilot\u00e9 par le CHU de Grenoble (Dr. Camille Verry) et concernera 100 patients.","breadcrumb":{"@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#primaryimage","url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2017\/05\/NHTheraguix-1.png","contentUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2017\/05\/NHTheraguix-1.png","width":900,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.inovallee.com\/nhtheraguix-passe-a-phase-2-de-essais-cliniques-metastases-cerebrales\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.inovallee.com\/"},{"@type":"ListItem","position":2,"name":"NHTheraguix passe \u00e0 la phase 2 de ses essais cliniques sur les m\u00e9tastases c\u00e9r\u00e9brales"}]},{"@type":"WebSite","@id":"https:\/\/www.inovallee.com\/#website","url":"https:\/\/www.inovallee.com\/","name":"inovall\u00e9e technopole, Home to software & smart technologies","description":"Home to software &amp; smart technologies","publisher":{"@id":"https:\/\/www.inovallee.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.inovallee.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.inovallee.com\/#organization","name":"inovall\u00e9e","url":"https:\/\/www.inovallee.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.inovallee.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2023\/08\/inovallee_2022_GrenobleAlpes.png","contentUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2023\/08\/inovallee_2022_GrenobleAlpes.png","width":945,"height":369,"caption":"inovall\u00e9e"},"image":{"@id":"https:\/\/www.inovallee.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/technopoleinovallee\/","https:\/\/x.com\/inovallee","https:\/\/www.linkedin.com\/company\/inovall-e\/","https:\/\/www.youtube.com\/user\/inovallee?reload=9"]},{"@type":"Person","@id":"https:\/\/www.inovallee.com\/#\/schema\/person\/a45b15518aad3111b2d61d257a3e023b","name":"Inovallee"}]}},"_links":{"self":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/18800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/comments?post=18800"}],"version-history":[{"count":0,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/18800\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/media\/12096"}],"wp:attachment":[{"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/media?parent=18800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/categories?post=18800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/tags?post=18800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}